Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lung Diseases 1Liposarcoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Nivolumab 11Specimen Handling 8Ipilimumab 7pembrolizumab 5CTLA-4 Antigen 5cabozantinib 4Magnetic Resonance Spectroscopy 4Biopsy 4Radiosurgery 3Axitinib 3pazopanib 2Sunitinib 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1lenvatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Nephrectomy 1Molecular Imaging 1Metastasectomy 1Inulin 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clear-cell metastatic renal cell carcinoma × sitravatinib × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡